Vertex Pharmaceuticals Incorporated Q3 2025 Earnings Recap

Vertex Pharmaceuticals reported a strong Q3 2025 performance with revenues of $3.08 billion, driven by robust growth in cystic fibrosis treatments and advancements in its renal disease pipeline.

Key Takeaways

• Achieved revenue of $3.08 billion, representing double-digit growth year-over-year.
• Continued strong uptake of ALYFTREK, qualifying 95% of CF patients for treatment, with significant clinical improvements reported.
• Progressing towards regulatory submissions for TRIKAFTA for ages 1-2, demonstrating unprecedented reductions in sweat chloride levels.
• Promising developments in the kidney portfolio, including initiation of Phase II studies for VX-407 and inaxaplin targeting serious renal diseases.
• Successful Phase IV trials for JOURNAVX in acute pain management indicate significant reductions in opioid use post-surgery.